Compare Braze Inc (BRZE) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Braze Inc vs Sanofi SA — how do they compare? Braze Inc trades at $27.58 (market cap $3.18B), while Sanofi SA trades at $43.59 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 32.8× Braze Inc's market cap, and Sanofi SA pays a 5.55% dividend while Braze Inc pays none. Which is the better fit depends on your goals.
| BRZE | SNY | |
|---|---|---|
Market Cap | $3.18B | $104.30B |
Sector | Technology | Health |
52-Week High | $36.19 | $52.34 |
52-Week Low | $15.79 | $41.33 |
Enterprise Value | $2.87B | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Braze (BRZE) trades at $27.71, down 3.62% today, with strong analyst support (96% buy ratings) and a $34.78 consensus price target. The stock shows bullish technical momentum despite recent earnings misses, with revenue growing 30% year-over-year to $593M in 2025. Recent news highlights insider selling and AI-driven sector recovery, while the company maintains robust gross margins of 66.5% but remains unprofitable with a -15.5% net margin.
The outlook remains positive based on accelerating revenue growth and strong institutional backing, though profitability challenges and recent insider selling present near-term risks. With technical indicators showing bullish momentum and the stock trading below analyst targets, BRZE offers growth potential but requires monitoring of execution on path to profitability.
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Braze Inc
Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail & E-commerce, Media & Entertainment, Financial Services, and Travel & Hospitality related industries.
Read more on BRZE →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
